Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder

NCT01585207 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
4
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Barbara J. Coffey